# Carcinoma of the Head of Pancreas

> A malignant tumour arising from the **exocrine pancreas**, typically **adenocarcinoma**, located in the **head** of the pancreas, often presenting with **painless obstructive jaundice**.

## History

- **Painless progressive jaundice**
- **Dark urine**, **pale stools**
- **Pruritus**
- **Weight loss**, **anorexia**
- **Epigastric pain** radiating to back (late feature)

## Physical Examination

- **Jaundice**
- **Scratch marks** (due to pruritus)
- **Courvoisier’s sign**: palpable, non-tender gallbladder with jaundice
- **Cachexia**, hepatomegaly

## Investigations

### Laboratory

1. **LFTs**: cholestatic pattern
   - ↑ Bilirubin (direct), ↑ ALP, ↑ GGT
1. **Tumour markers**:
   - **CA 19-9** (elevated in \~80% of cases)
   - **CEA** (less specific)

### Imaging

1. **Ultrasound abdomen**
   - Biliary duct dilation, mass in pancreatic head
1. **Contrast-enhanced CT (CECT)**
   - Gold standard for diagnosis and staging
1. **MRI/MRCP**
   - Excellent for biliary and pancreatic duct anatomy
1. **Endoscopic Ultrasound (EUS)**
   - Tissue biopsy (fine needle aspiration)
1. **ERCP**
   - For biliary stenting if obstructive jaundice
1. **PET-CT**
   - For detecting distant metastasis in selected cases

## Management

### A. Resectable Disease (\~20% of cases)

#### Indications for Surgery

- No major vessel invasion (SMA, SMV, portal vein)
- No distant metastasis
- Good performance status

#### Pre-op Preparation

- Nutritional optimization
- Biliary drainage (only if severe cholestasis or cholangitis)
- Staging laparoscopy (to exclude occult metastasis)

#### Surgery: `Whipple Procedure` (Pancreaticoduodenectomy)

- Resection of:
  - Head of pancreas
  - Duodenum
  - Distal bile duct
  - Gallbladder
  - +/- Distal stomach (standard vs pylorus-preserving)
- Reconstruction: `pancreaticojejunostomy`, `hepaticojejunostomy`, `gastrojejunostomy`

#### Post-op Complications

- Pancreatic fistula
- Delayed gastric emptying
- Infections
- Diabetes mellitus
- Anastomotic leak

### B. Unresectable or Locally Advanced Disease

#### Palliative Options

- **Endoscopic biliary stenting** (ERCP)
- **Percutaneous transhepatic biliary drainage (PTBD)**
- **Gastrojejunostomy** (if duodenal obstruction)
- **Pain management** (morphine, celiac plexus block)
- **Palliative chemotherapy**

### C. Metastatic Disease

- Systemic chemotherapy (palliative intent)
- Symptom management: pain, jaundice, anorexia
- Psychological and palliative support

## Prognosis

- Overall 5-year survival: **< 10%**
- With R0 resection: \~20–25%
- Median survival:
  - Resected: \~20–24 months
  - Unresectable/metastatic: \~6–12 months

## Prevention and Surveillance

- No established screening for general population
- High-risk groups (e.g., familial pancreatic cancer syndromes) → MRI/EUS screening
